Last updated: 11/04/2018 04:24:59

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Request patient level data
GSK study ID
AC2103473
See study documents
Clinicaltrials.gov ID
NCT00279019
EudraCT ID
2005-002093-30
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients
Trial description: GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK233705 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary disease.
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK233705 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary disease.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Adverse events, blood pressure, heart rate, 12-lead electrocardiogram (ECG), Holter and Lead II ECG monitoring, ECG, lung function and clinical laboratory safety tests.

Timeframe: Up to Week 12

Secondary outcomes:

Plasma and urine concentrations of GSK233705 and derived pharmacokinetic parameters. Serial IOS and FEV1 measurements over 27 hours post-dose Serial sGaw, Raw measurements over 24 hours post-dose.

Timeframe: Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours Post-dose

Interventions:
  • Drug: GSK233705
  • Drug: Tiotropium
  • Drug: Placebo
    • Enrollment:
    31
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Pulmonary Disease, Chronic Obstructive
    Product
    darotropium bromide
    Collaborators
    Not applicable
    Study date(s)
    December 2005 to June 2006
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    40 - 75 years
    Accepts healthy volunteers
    No
    • Inclusion criteria:
    • Of non-childbearing potential.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Inclusion criteria:
    • Of non-childbearing potential.
    • Diagnosed with COPD, as defined by the GOLD guidelines.
    • Smoker or an ex-smoker with a smoking history of at least 10 pack years.
    • FEV1/FVC < 0.7 post-bronchodilator (salbutamol).
    • FEV1 <= 80% of predicted normal for height, age and gender after inhalation of salbutamol.
    • Response to ipratropium bromide 9.
    • Subject's weight is 60kg. Exclusion criteria:
    • Past or present disease, which as judged by the Investigator and the Medical Monitor, may affect the outcome of this study.
    • FEV1 <=50% of predicted after inhalation of salbutamol.
    • Tested positive for hepatitis C antibody, hepatitis B surface antigen or HIV.
    • Has claustrophobia that may be aggravated by entering the plethysmography cabinet.
    • Has prostate hypertrophy or narrow angle glaucoma.
    • Diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, allergic rhinitis, or asthma.
    • Poorly controlled COPD.
    • Participated in a Pulmonary Rehabilitation Program within 4 weeks prior to screening visit or will enter a program during the study.
    • Had a respiratory tract infection in the 4 weeks prior to the screening visit and throughout the duration of the study.
    • History of congestive heart failure, coronary insufficiency or cardiac arrhythmia.
    • A mean QTc(B) value at screening >440msec, the QTc(B) of all 3 screening ECGs are not within 10% of the mean, a PR interval outside the range 120-210msec or an ECG that is not suitable for QT measurements.
    • A history of elevated supine blood pressure or a mean blood pressure equal to or higher than 160/95 mmHg.
    • A mean heart rate outside the range 40-90 bpm.
    • QTc prolongation >470msec or risk factors for torsades de pointes (heart failure NYHA II-IV, hypokalaemia, familial long QT syndrome).
    • Receiving co-medication with drugs which prolong the QTc interval.
    • Requires treatment with inhaled cromolyn sodium or nedocromil, oral beta-2-agonists, nebulised beta-2-agonists, nebulised anticholinergics or leukotriene modifiers.
    • Unable to abstain from xanthines (other than caffeine.
    • Unable to abstain from short-acting inhaled bronchodilators.
    • Unable to abstain from long-acting inhaled bronchodilators.
    • Changed dose of inhaled or oral corticosteroids within the last 6 weeks.
    • Taking more than 10mg/day of prednisolone (or equivalent).
    • Receiving treatment with long term or short-term oxygen therapy or requires nocturnal positive pressure for sleep apnea.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein, Germany, 22927
    Status
    Terminated/Withdrawn
    Contact us
    Location
    GSK Investigational Site
    Berlin, Berlin, Germany, 14050
    Status
    Terminated/Withdrawn
    Contact us
    Location
    GSK Investigational Site
    Hannover, Niedersachsen, Germany, 30625
    Status
    Terminated/Withdrawn
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2006-13-06

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Results for study AC2103473 can be found on the GSK Clinical Study Register.
    Click here
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website